SCYNEXIS INC. news, videos and press releases
For more news please use our advanced search feature.
SCYNEXIS INC. - More news...
SCYNEXIS INC. - More news...
- SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
- SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
- SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
- SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
- SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
- SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
- SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
- SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
- SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
- SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
- SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
- Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- SCYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX
- SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
- SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
- SCYNEXIS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
- SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX
- SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
- SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
- TOP RANKED ROSEN LAW FIRM Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
- SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
- SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX
- SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
- SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
- ROSEN, A TOP RANKED LAW FIRM, Encourages SCYNEXIS, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
